Policy & Recommendations
The European public health response to the COVID-19 pandemic: Lessons for future cross-border health threats
The early lessons from the pandemic underlined that challenges to health systems and economies, including supply chain problems and vaccine hesitancy, could no longer be overcome by European Union Member States acting alone.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has been dominant in Europe since January 2022, causing large waves of infections because of high transmissibility and escape from vaccine- and infection-induced immunity.
Influenza vaccination in patients affected by diabetes
The effects of vaccination appear to be more effective when using higher-dose and quadrivalent vaccines, although subgroup-specific separate analyses in patients with diabetes are lacking.
COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022
COVID-19 vaccine effectiveness decreased with waning of vaccine-derived immunity and emerging Omicron sublineages.
Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England
Seasonal vaccination against influenza and in-pandemic COVID-19 vaccination are top public health priorities; vaccines are the primary means of reducing infections and also controlling pressures on health systems.
A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season.
Pharmacists are encouraged to speak to members of their community about getting both the flu and COVID-19 vaccines at the same time
This 2022-23 flu season in the Northern Hemisphere arrived earlier than expected and we are also seeing a concerning increase in the number of respiratory syncytial virus (RSV) cases.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic
The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication.
Policy & Recommendations
Council calls for combatting vaccine hesitancy and closer EU cooperation
EU Ministers of Health approved Council conclusions on vaccination as one of the most effective tools for preventing disease and improving public health.
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains.